Healthcare tech company Privia Health Group (NASDAQ: PRVA) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 13.2% year on year to $657 million. The company’s full-year revenue guidance of $2.53 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP profit of $0.21 per share was 11.8% below analysts’ consensus estimates.

Is now the time to buy PRVA? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Privia Health’s latest quarter was marked by strong sales growth and a positive market response, with revenue rising 13.2% year-over-year and outperforming Wall Street’s expectations. Management attributed this momentum to robust new provider signings and steady expansion in value-based care arrangements. CEO Parth Mehrotra highlighted operational scale as a key driver, stating, “We delivered robust new provider signings, giving us clear visibility into our implementation pipeline for the remainder of 2026 and into 2027.”

Looking ahead, Privia Health’s updated guidance emphasizes continued expansion through both organic provider growth and targeted acquisitions, as well as a disciplined approach to capital deployment. Management expects the recent acquisition of American Choice Healthcare to broaden the company’s footprint across new states, while organic sales and a diversified value-based care strategy remain foundational. Mehrotra noted, “Given our strong year-to-date results, we are raising our 2026 outlook above the high end of our initial guidance for all key financial metrics.”

Key insights from management’s remarks

Management attributed the quarter’s revenue outperformance to growth in implemented providers, expansion in value-based care, and the integration of newly acquired practices, while acknowledging non-GAAP profitability was below expectations due to scaling and mix effects.

• Provider network expansion: Privia Health added 249 providers sequentially, reaching 5,893 implemented providers and growing its footprint across 25 states and the District of Columbia. This expansion drove higher practice collections and allowed for greater local density in key markets.
• Value-based care momentum: Attributed lives in value-based arrangements rose 19.2% from last year, including commercial, Medicare Advantage, and Medicaid programs. Management highlighted growth in commercial contracts as a differentiator, with 966,000 commercial attributed lives and increased engagement with payers to share risk in cost and quality outcomes.
• Acquisition strategy: The company announced the acquisition of American Choice Healthcare’s Medicare Shared Savings Program ACO, adding 36,000 attributed lives across 10 existing states and three new states for $36 million in cash, with the goal of expanding the care partners’ value-based care footprint. Management emphasized the attractiveness of acquiring assets at low multiples and integrating them for long-term growth.
• Montana partnership exit: Privia Health is exiting its partnership in Montana, which involved 69 providers and $23 million in annual practice collections. Management cited strategic prioritization and scale considerations, noting the exit will have no material impact on EBITDA in 2027.
• Operating leverage and margin trends: While adjusted EBITDA margin as a percentage of care margin increased to 28.8% year-to-date, non-GAAP EPS missed expectations. Management attributed this to increased operating costs from scaling, acquisition integration, and the impact of transitioning administrative services assets to full GAAP revenue recognition.

Drivers of future performance

Privia Health’s outlook is shaped by provider growth, disciplined M&A, and a focus on scaling value-based care while navigating evolving reimbursement and regulatory conditions.

• Organic and inorganic growth: Management is relying on both internal provider recruitment and selective acquisitions to drive expansion into new and existing markets. The company remains disciplined in targeting accretive deals, leveraging its balance sheet strength for flexibility.
• Value-based care diversification: Continued scaling of commercial and government value-based contracts is expected to support revenue and margin growth. The company is focused on increasing attributed lives while balancing exposure across commercial, Medicare Advantage, and Medicaid programs to mitigate regulatory or market-specific risks.
• Cost structure and margin management: Privia intends to maintain G&A and operating costs below care margin growth, targeting EBITDA-to-care margin conversion in the high end of its 30%-35% range. Management acknowledged that while cost trends are stable, there is variability in utilization and reimbursement that could affect profitability, especially as the company integrates new acquisitions.

Catalysts in upcoming quarters

Going forward, the StockStory team will be closely tracking (1) the integration and early contributions from the American Choice Healthcare acquisition, especially across new states; (2) the pace of provider recruitment and onboarding, which underpins both organic and value-based care growth; and (3) management’s ability to sustain EBITDA margin expansion while absorbing new practices and navigating reimbursement changes. We will also monitor any strategic capital deployment or share repurchase decisions as cash balances build.

Privia Health currently trades at $23.93, up from $22.40 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.